Anlotinib and 14C-labeled Anlotinib

Phase 3Small molecule

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Anlotinib and 14C-labeled Anlotinib is one of 30 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaRecruiting

Hepatocellular CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Anlotinib and 14C-labeled Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Cysteine Hydrochloride

Novartis

Preclinical

1 6

Hepsera

Coreg

2 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

Vermox

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Hepatocellular Carcinoma

NCT05862337

Q2 2029

Phase 3Not yet recruiting

Endometrial Cancer

NCT06475599

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06475599·420 enrolled

Hepatocellular Carcinoma1 trial

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05862337·480 enrolled

Advanced Cancer1 trial

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT02622932·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Anlotinib and 14C-labeled Anlotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anlotinib and 14C-labeled Anlotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anlotinib and 14C-labeled Anlotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chia Tai Tianqing Pharmaceutical Group Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Anlotinib and 14C-labeled Anlotinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Trials by Indication[1]

Endometrial Cancer1 trial

Hepatocellular Carcinoma1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News